AAA
FBRX

Affinity Asset Advisors’s Forte Biosciences FBRX Stock Holding History

Affinity Asset Advisors’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,400
Closed -$611K – 110
2025
Q4 		$611K Buy
+22,400
New +$393K 0.03% 91

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Affinity Asset Advisors's FBRX Position: Q2 2026 in Review

Affinity Asset Advisors increased its Forte Biosciences (FBRX) stake by 13% in Q2 2026, buying an estimated $3.17M and bringing the position to 1,145,391 shares worth $24.3M. The position accounts for 1.1% of the portfolio, ranked #28.

Affinity Asset Advisors first reported a position in FBRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $27M in Q4 2025. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Affinity Asset Advisors held 1,145,391 shares of Forte Biosciences worth $24.3M as of Q2 2026.
  • Affinity Asset Advisors bought 133,501 Forte Biosciences shares in Q2 2026, an estimated $3.17M.
  • Forte Biosciences made up 1.1% of Affinity Asset Advisors's portfolio in Q2 2026, its #28 holding.
  • Affinity Asset Advisors first reported a position in Forte Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Affinity Asset Advisors's Forte Biosciences position peaked at $27M in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.